Fig. 1.

SARS-CoV-2 specific T-cell responses were increased in COVID-19 patients without a cancer history compared to COVID-19 patients with solid or haematological malignancies. PBMCs from 21 healthy donors and COVID-19 patients without a cancer history (n = 29), solid tumour (n = 28) or haematological malignancies were analysed for SARS-CoV-2 and antiviral-specific T-cell responses by IFNγ ELISpot assay. A. Frequency of patients with specific responses to at least one SARS-CoV-2 protein. B. Frequencies (%) of positive SARS-CoV-2 specific immune responses in healthy donors and COVID-19 patients (Mann–Whitney test, ∗p > 0.05). C. Frequency (%) of positive antiviral memory CD8 T-cell responses in healthy donors and COVID-19 patients. D. The median serology index (S/CO) in COVID-19 patients without a cancer history, solid tumour or haematological malignancies (Mann–Whitney test, ∗p > 0.05, ∗∗p > 0.01). E. Heatmap showing the positivity or the negativity of the serology index, T-cell immune responses to SARS-CoV-S, M and N proteins for each patient included in the study (online Morpheus software). Healthy donors' population is represented by light gray, COVID-19 patients without a cancer history by black, COVID-19 patients with solid tumour by blue and haematological malignancies by violet. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)